Thrombotic microangiopathy after stem cell transplant in adults
Part of Blood & lymphatic clinical trials.
This study looks at people who have a blood clotting problem called TMA after a stem cell transplant from a donor. It gathers information from routine checkups to learn more about this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have received a donor stem cell transplant (allogeneic HSCT)
- You have had at least 3 signs of TMA (like broken red blood cells, high LDH, low platelets, anemia, high blood pressure, or protein in urine) in two checks within 2 weeks
- You are not in another study that tests a treatment for TMA
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medicine called iptacopan for people who have a serious blood vessel complication after a stem cell transplant (TA-TMA) that is not improving with usual treatments. The goal is to see if iptacopan can help stop the damage and improve recovery.
This study tracks patients who receive a stem cell transplant from a donor to see how often they develop a blood condition called transplant-associated thrombotic microangiopathy (TA-TMA). The goal is to identify patients at higher risk and monitor them closely for this condition.
This study looks at how two immune system proteins, interferon and complement, are involved in a rare condition called thrombotic microangiopathy (TMA) that can damage small blood vessels after a stem cell or organ transplant. Understanding these proteins may help doctors find better treatments for TMA and related complications.
This trial looks for proteins in the blood that could help detect transplant-related blood vessel damage (called TMA) earlier, so doctors can treat it faster. It involves patients who have had a stem cell transplant from a donor.
This study tests a new medicine called TGD001 for people with a group of rare blood disorders called thrombotic microangiopathies (TMAs), where small blood clots form and damage organs. The goal is to see if TGD001 can help stop the clotting and improve outcomes.
This trial tests whether eculizumab can safely help people with a serious blood vessel complication called TA-TMA after a stem cell transplant. You may be eligible if you have high-risk features and haven't improved with initial care.
Hear when a new Thrombotic Microangiopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.